Recent Articles
Weekly Psychedelic Policy Briefing – August 16, 2026
Resilient Pharmaceuticals has resubmitted its New Drug Application for MDMA-assisted therapy for PTSD, without the new Phase 3 trial the FDA asked for. Canada funds a C$24 million cannabis and brain health consortium, and Definium’s oral LSD tablet clears Phase 3 in generalized anxiety disorder.
By Jack Gorsline
Filter
Ibogaine’s Moment Has Arrived. Are We Ready to Meet It?
MAPS co-executive director Ismail Lourido Ali on what the April 2026 executive order, the Texas…
By Ismail L. Ali, JD
The Post-Psychedelic Challenges Study: A Vital New Frontier in Psychedelic Science
An Emory study is recruiting 800 people who faced post-psychedelic challenges, to learn what recovery…
By Josh Lipson, PhD and Roman Palitsky, MDiv, PhD
Weekly Psychedelic Policy Briefing – August 2, 2026
The House attached psychedelic amendments to the FY2027 defense bill, VA Secretary Doug Collins promoted…
By Jack Gorsline
Psilocybin Trial in Veterans With Treatment-Resistant PTSD Reports 75% Remission at One Month
Nine of twelve veterans with severe, treatment-resistant PTSD no longer met diagnostic criteria a month…
By Joe Moore
Psychedelic Policy Briefing: Week of July 27th, 2026
The House voted to extend the Pentagon’s psychedelic research program through 2033, then blocked a…
By Jack Gorsline
Five Phases, Eight Circuits: Chinese Medicine as a Map for Psychedelic Consciousness
Douglas Wingate, a Doctor of Traditional Chinese Medicine and licensed Oregon psilocybin facilitator, maps the…